Save up -80% on Mepolizumab
Note: this is a drug discount program, not an insurance plan.
2018 Price of Mepolizumab
* price without discount in nearest pharmacy. Price may vary.
We offer free Mepolizumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Mepolizumab every time. What are you waiting for? Claim your prescription drug card now!
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Mepolizumab
Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells. It has a molecular weight of approximately 149 kDa. It was approved by the FDA in November, 2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline). Mepolizumab has been investigated in the treatment of severe nasal polyposis, among numerous other conditions.
Mepolizumab mechanism of action
Mepolizumab is an interleukin-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of mepolizumab action in asthma has not been definitively established.
Dosage forms of Mepolizumab
|Injection, powder, for solution||subcutaneous||100 mg/mL|
|Powder for solution||subcutaneous||144 mg|
Humans and other mammals
Indication of Mepolizumab
Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/ l at initiation of treatment or blood eosinophils greater than or equal to 300 cells/ l in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
Toxicity of Mepolizumab
RX24 Drugs Disclaimer: before buying a Mepolizumab on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.